Getty Images Two breakthrough Alzheimer’s drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The medicines are the first to slow the disease, which may give people extra time living independently. The National Institute for Health and Care Excellence (NICE) concluded they were a poor use of...
